ClinicalTrials.gg
RecruitingNCT05161429BESTMEDUpdated Jun 22, 2023

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

An observational study in Diabetes Mellitus, Type 2, sponsored by Brigham and Women's Hospital. Recruiting at 5 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Brigham and Women's Hospital · Observational

How we know · 5 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
550,000
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital — 4 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Brigham and Women's Hospital.

Planned enrollment
2nd of 24
550,000 · median 33,866
Started
2021
with 2 others
Observational
25 of 45
2 open now
Registered
23rd of 45
by date

Among the 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital, this one is the 2nd largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2021, is one of 25 observational ones, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.

Read the detailed description

Type 2 diabetes is an increasingly common disease that affects more than 10 percent of adults in the United States. Multiple medications are available to treat this condition. However, many of these medications have never been directly compared against one another, which makes it unclear which medication is the best to use.

Investigators will use a large database of electronic patient data to compare diabetes medications to determine which ones offer the best balance of risks and benefits. This database will draw from several large healthcare institutions and health insurance companies that collectively pull from a patient population of over 130 million across all major regions of the United States. Investigators will study adults aged 30 or older who have type 2 diabetes and are at moderate risk of heart attacks and strokes, and who are starting a second diabetes medication (after metformin). Investigators will use clinical trial emulation, a cutting-edge statistical technique, to compare the following classes of diabetes medications: (1) DPP4 inhibitors (alogliptin, linagliptin, sitagliptin, or saxagliptin); (2) GLP1 receptor agonists (dulaglutide, exenatide, liraglutide, or semaglutide); (3) basal insulin (degludec, detemir, glargine, or NPH); (4) SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin); and (5) sulfonylureas (glimepiride, glipizide, or glyburide).

To determine which diabetes medications provide the greatest benefit to patients, investigators will compare how much they reduce the risks of the following \conditions: (1) heart attack; (2) heart failure; (3) stroke; (4) kidney disease; (5) eye disease; and (6) liver disease. To allow patients with diabetes and their doctors to make fully informed decisions about which diabetes medication to take, investigators will also compare these medications' risks of the following possible side effects: (1) low blood sugar; (2) kidney infection; (3) severe skin infections in the genital area; (4) foot/leg amputations; (5) broken bones; (6) pancreatitis (i.e., severe inflammation of the pancreas); (7) pancreatic cancer; (8) thyroid cancer; and (9) death from causes other than heart attacks or strokes.

In order to minimize the risk of bias and confounding, the analysis will be conducted using causal inference techniques, by emulating a randomized clinical trial (including both intention-to-treat and per-protocol analyses), while incorporating rigorous data quality checks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is adults aged 30 or older who have type 2 diabetes and are at moderate risk of Atherosclerotic Cardiovascular Disease (ASCVD), and who are starting a second diabetes medication (after metformin). Patients from collaborating institutions will be included in the analysis based on study population inclusion and exclusion criteria.

Eligibility criteria

Individuals meeting the following criteria between January 1, 2015 and December 31, 2021:

  • Diabetes mellitus (DM) type II
  • of 7-11% within the past year
  • Monotherapy with metformin for at least 3 months
  • No prior non-metformin outpatient diabetes therapy
  • Aged ≥30y
  • At "moderate" risk of ASCVD

    • Men aged ≥35y and women aged ≥45y with no history* of stroke, myocardial infarction, revascularization, or heart failure hospitalization
    • Men aged 30-34 and women aged 30-44 with history* of hypertension, hyperlipidemia, retinopathy, kidney disease or neuropathy
  • estimated (eGFR) ≥ 45 ml/min/1.73m2 within the past 3 years
  • Not pregnant at time 0
  • No history* of institutionalization with a diagnosis of dementia, cancer, end stage lung disease, end stage liver disease, pancreatitis, medullary thyroid cancer or severe UTIs
  • Engagement with the healthcare system: enrollment for at least 12 months and attendance of at least one outpatient encounter in the prior 12 months

(*) History will be derived from at least 12 months of EHR and claims prior to time zero and will use all available EHR and claims data between January 1, 2014 and time zero

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
550,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • DPP4

    Patients receiving second line diabetes treatment with dipeptidyl peptidase-4 inhibitors (DPP4) following metformin

    Drug: DPP4

  • GLP1-RA

    Patients receiving second line diabetes treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) following metformin

    Drug: GLP-1 receptor agonist

  • Basal insulin

    Patients receiving second line diabetes treatment with basal insulin following metformin

    Drug: Basal Insulin

  • SLGT2

    Patients receiving second line diabetes treatment with sodium-glucose cotransporter-2 inhibitors (SLGT2) following metformin

    Drug: SLGT2

  • SU

    Patients receiving second line diabetes treatment with sulfonylureas (SU) following metformin

    Drug: SU

Interventions

  • DrugDipeptidyl Peptidase 4Studies of Dipeptidyl Peptidase 4Dipeptidyl Peptidase 4 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin

  • DrugGLP-1 MimeticStudies of GLP-1 MimeticGLP-1 Mimetic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide

  • DrugBasal Insulin

    degludec, detemir, glargine and NPH

  • DrugSLGT2

    Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin

  • DrugSU

    Sulfonylurea (SU) including glimepiride, glipizide, and glyburide

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. 4-point major adverse cardiac events (MACE)

    Includes: a) death from cardiovascular causes b) non-fatal myocardial infarction (MI) c) non-fatal stroke and d) hospitalization for heart failure (HF)

    Time frame: Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.

  2. 3-point major adverse cardiac events (MACE)

    Includes: a) death from cardiovascular causes as reported in the National Death Index b) non-fatal MI and c) non-fatal stroke

    Time frame: Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.

Secondary outcomes

  1. Adverse outcomes

    Includes a) severe hypoglycemia b) severe urinary tract infection (UTI) c) Fournier's gangrene d) lower extremity amputation e) bone fracture f) diabetic ketoacidosis (DKA) g) pancreatitis h) pancreatic cancer i) medullary thyroid cancer j) non-cardiovascular death

    Time frame: Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.

  2. Severe clinical outcomes

    Includes: a) hospitalization for \>= 30 days with any of the primary or secondary outcome endpoints as the primary or admitting diagnosis b) ICU admission with any of the primary or secondary outcome endpoints as the primary or admitting diagnosis or c) death from any cause

    Time frame: Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.

  3. Non-cardiovascular outcomes

    Includes a) nephropathy b) diabetic retinopathy requiring treatment c) non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis / nonalcoholic steatohepatitis (NASH)

    Time frame: Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.

07

Study locations

5 of 5 sites recruiting
  • HealthCore, Inc.
    Wilmington, Delaware 19801, United States
    Recruiting
    • Vincent Willey, PharmD · Contact
  • Humana
    Lexington, Kentucky 40512-4611, United States
    Recruiting
    • Vinit Nair, MS, RPh · Contact
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Alexander Turchin, MD, MS · Contact
  • Greater Plains Collaborative
    Beachwood, Ohio 44122, United States
    Recruiting
    • Ryan Carnahan, PhD · Contact
  • Baylor Scott & White
    Dallas, Texas 75246, United States
    Recruiting
    • Heather Kitzman Carmichael, PhD · Contact
08

References and documents

Publications

  • Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May 12;97(18):1837-47. doi: 10.1161/01.cir.97.18.1837. PubMed 9603539 ↗
  • D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994 Jan;25(1):40-3. doi: 10.1161/01.str.25.1.40. PubMed 8266381 ↗
  • Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999 Jun 14;159(11):1197-204. doi: 10.1001/archinte.159.11.1197. PubMed 10371227 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Jun 2024, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2021
First posted
Dec 17, 2021
StartActual
Jul 1, 2021
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161429
Collaborators
Patient-Centered Outcomes Research Institute, Baylor College of Medicine, Baylor Scott and White Research Institute, The Cleveland Clinic, HealthCore, Inc., Humana Inc., Massachusetts General Hospital, Medical Outcomes Management, University of Iowa, Allina Health, Intermountain Health Care, Inc., Marshfield Clinic, Medical College of Wisconsin, University of Missouri-Columbia, University of Utah
Responsible party
Alexander Turchin (Associate Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Dec 17, 2021
Start date
Jul 1, 2021
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Jun 22, 2023

Study contacts

Emma Hegermiller, MS
Contact
emma@bestmed.org
617-732-5661
Alexander Turchin, MD, MS
Contact
aturchin@bwh.harvard.edu
617-732-5661
Alexander Turchin, MD, MS
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion